In a recent podcast episode of ‘Beyond Biotech’ - the podcast from Labiotech – Partner Roel Meers shares insights on how biotech companies are navigating a volatile financial landscape in 2025.
“We’re in dynamic times. IPOs may be quiet, but great ideas are still coming into existence — and there’s strong interest in investing at the early stages.”
Roel discusses how investors are de-risking deals, the rise of licensing over M&A, and how European biotechs can position themselves for long-term success.
Listen to the full episode here: https://podcast.labiotech.eu/1995493/episodes/17195943-the-state-of-biotech-finance-and-fundraising-in-q2-2025-with-baker-mackenzie
